Agenolab, the Stuttgart-based service provider, is the first company in Germany to expand its service offering with the latest cell-analysis technology from Roche.
The company will use the RTCA Cardio instrument to complement its analytical service portfolio for drug development.
The RTCA Cardio Instrument, a medium-throughput cell analyser, utilises impedance readings to monitor cardiac beating and cellular events in real time, featuring a new detection-rate and frequency-measurement concept, as well as dedicated software.
Unlike synergistic techniques, such as the patch clamp, the system can be used in a fully controlled environment for continuous short-term and long-term experiments, thus improving the applicable experimental time as well as the reproducibility and data quality.
The instrument is said to be the only 96-well, cardiotoxicity screening system on the market for continuous, real-time, label-free cardiomyocyte beating analysis.
It can be used in conjunction with cardiomyocytes derived from human or mouse stem cells for assessing the cardiac safety profile of lead compounds or drug candidates during drug development.
